TrialThe lancet. HIV2019

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Beatriz Grinsztejn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.